SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 17, 2002; DOI 10.1182/blood-2002-01-0022. This Article Full Text (PDF) All Versions of this Article: 2002-01-0022v1 100/3/845    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Buschfort-Papewalis, C. Articles by Thomale, J. Search for Related Content PubMed PubMed Citation Articles by Buschfort-Papewalis, C. Articles by Thomale, J. Social Bookmarking                   What's this? Submitted January 3, 2002 Accepted February 25, 2002 Down-regulation of DNA repair in human CD34+ progenitor cells corresponds to increased drug sensitivity and apoptotic response Claudia Buschfort-Papewalis, Thomas Moritz, Bernd Liedert, and Jurgen Thomale* Institute of Cell Biology, University of Essen Medical School, Essen, Germany * Corresponding author; email: juergen.thomale{at}uni-essen.de. While DNA repair processes have been shown to considerably modulate the cytotoxic effects of alkylating agents, little information is available on the role of these mechanisms in chemotherapy-induced myelosuppression. Therefore, we have analyzed in detail the DNA repair capacity of primary human hematopoietic cells from cord blood (CB) or bone marrow (BM) by two functional assays, the immuno-cytological assay (ICA) and single-cell gel electrophoresis (comet assay). Besides substantial interindividual differences, we consistently observed significantly lower repair capacity of CD34+ cells in comparison to CD34-, CD19+, or CD33+ cells of the same donor. After exposure to the alkylating agent ethylnitrosourea (EtNU), the comet assay displayed on average twice as many DNA single-strand breaks (SSB) in CD34+ cells and a tripled half life of these lesions in comparison to corresponding CD34- cells. Similarly, reduced SSB repair activity in CD34+ cells was detected following melphalan or cisplatin application. When specific antibodies were used to monitor DNA reaction products of these drugs, adduct levels were significantly higher and lesions persisted longer in the CD34+ fraction. To assess the contribution of individual pathways to overall DNA repair, modulators blocking defined steps in repair processes were co-applied with alkylating drugs. Similar "modulation pattern" in corresponding CD34+ and CD34- cell fractions indicated a generalised reduction in DNA repair capacity of CD34+ cells, rather than deficiencies in a specific pathway. As CD34+ cells also displayed higher frequencies of apoptosis in response to melphalan or cisplatin, these findings may help to explain the myelosuppression after exposure to alkylating agents. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Arab, M. Pedersen, J. Nair, M. Meerang, L. E. Knudsen, and H. Bartsch Typical signature of DNA damage in white blood cells: a pilot study on etheno adducts in Danish mother-newborn child pairs Carcinogenesis, February 1, 2009; 30(2): 282 - 285. [Abstract] [Full Text] [PDF] M. D. Milsom, M. Jerabek-Willemsen, C. E. Harris, A. Schambach, E. Broun, J. Bailey, M. Jansen, D. Schleimer, K. Nattamai, J. Wilhelm, et al. Reciprocal Relationship between O6-Methylguanine-DNA Methyltransferase P140K Expression Level and Chemoprotection of Hematopoietic Stem Cells Cancer Res., August 1, 2008; 68(15): 6171 - 6180. [Abstract] [Full Text] [PDF] A. Dzagnidze, Z. Katsarava, J. Makhalova, B. Liedert, M.-S. Yoon, H. Kaube, V. Limmroth, and J. Thomale Repair Capacity for Platinum-DNA Adducts Determines the Severity of Cisplatin-Induced Peripheral Neuropathy J. Neurosci., August 29, 2007; 27(35): 9451 - 9457. [Abstract] [Full Text] [PDF] J. P. Thomas, J. Lautermann, B. Liedert, F. Seiler, and J. Thomale High Accumulation of Platinum-DNA Adducts in Strial Marginal Cells of the Cochlea Is an Early Event in Cisplatin but Not Carboplatin Ototoxicity Mol. Pharmacol., July 1, 2006; 70(1): 23 - 29. [Abstract] [Full Text] [PDF] J. van Grevenynghe, M. Bernard, S. Langouet, C. Le Berre, T. Fest, and O. Fardel Human CD34-Positive Hematopoietic Stem Cells Constitute Targets for Carcinogenic Polycyclic Aromatic Hydrocarbons J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 693 - 702. [Abstract] [Full Text] [PDF] P. J. Real, Y. Cao, R. Wang, Z. Nikolovska-Coleska, J. Sanz-Ortiz, S. Wang, and J. L. Fernandez-Luna Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2 Cancer Res., November 1, 2004; 64(21): 7947 - 7953. [Abstract] [Full Text] [PDF] D. J. Abernethy, E. V. Kleymenova, J. Rose, L. Recio, and B. Faiola Human CD34+ Hematopoietic Progenitor Cells Are Sensitive Targets for Toxicity Induced by 1,4-Benzoquinone Toxicol. Sci., May 1, 2004; 79(1): 82 - 89. [Abstract] [Full Text] [PDF] A. Tripp, Y. Liu, M. Sieburg, J. Montalbano, S. Wrzesinski, and G. Feuer Human T-Cell Leukemia Virus Type 1 Tax Oncoprotein Suppression of Multilineage Hematopoiesis of CD34+ Cells In Vitro J. Virol., November 15, 2003; 77(22): 12152 - 12164. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020